|
|
Article: Collegium Pharmaceutical Inc. Receives Notice of Allowance for US Patent for Novel Dosage Form for Combination Products.
- Article from:
- Business Wire
- Article date:
- September 23, 2004
CopyrightCOPYRIGHT 2004 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
CUMBERLAND, R.I. -- Collegium Pharmaceutical, Inc., a development company for specialty pharmaceutical products, today announced that it has received notice of allowance from the U.S. Patent and Trademark Office (PTO) for its patent application "Pharmaceutical Composition for Compressed Annular Tablet with Molded Triturate Tablet for Both Intraoral and Oral Administration", US Patent 10015930. This patented technology trademarked 'MEDI-SAVER(TM)' is a unique dosage form consisting of a tablet triturate molded within an annular tablet providing for both intraoral (e.g. sub-lingual) and subsequent oral administration. It is a two component pharmaceutical composition that ...
Related newspaper, magazine, and journal articles:
|
|
Article: FDA accepts Collegium's opioid product IND.(Food and Drug ...
Pharma Marketletter;
July 23, 2007 ;
700+ words
...Rhode Island, USA-based specialty drug firm Collegium Pharmaceutical says that the Investigational New Drug Application ... DETERx technology and is a sustained-release oral dosage form designed to be more resistant to tampering and ...
|
|